Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

BACKGROUND: Women with epithelial ovarian cancer (OC) have a higher chance to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant. Current guidelines advise BRCA1/2 genetic predisposition testing for all OC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Vos, Janet R, Fakkert, Ingrid E, de Hullu, Joanne A, van Altena, Anne M, Sie, Aisha S, Ouchene, Hicham, Willems, Riki W, Nagtegaal, Iris D, Jongmans, Marjolijn C J, Mensenkamp, Arjen R, Woldringh, Gwendolyn H, Bulten, Johan, Leter, Edward M, Kets, C Marleen, Simons, Michiel, Ligtenberg, Marjolijn J L, Hoogerbrugge, Nicoline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019087/
https://www.ncbi.nlm.nih.gov/pubmed/31076742
http://dx.doi.org/10.1093/jnci/djz080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019087/
https://www.ncbi.nlm.nih.gov/pubmed/31076742
http://dx.doi.org/10.1093/jnci/djz080

Ejemplares similares